Dimensional Fund Advisors LP Reduces Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Dimensional Fund Advisors LP lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 267,928 shares of the company’s stock after selling 9,427 shares during the period. Dimensional Fund Advisors LP’s holdings in Medpace were worth $89,018,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Lindbrook Capital LLC boosted its position in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the last quarter. HBK Sorce Advisory LLC boosted its position in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. boosted its position in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after buying an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its position in Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. William Blair restated a “market perform” rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen lowered Medpace from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Mizuho lowered their price objective on Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. Robert W. Baird decreased their target price on Medpace from $340.00 to $313.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 23rd. Finally, Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $349.30.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm’s stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company’s stock, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 20.30% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $298.18 on Tuesday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The company has a market cap of $8.57 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.81 and a beta of 1.46. The business has a fifty day moving average price of $312.88 and a 200 day moving average price of $331.26.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period last year, the company earned $3.20 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.